Jornal Vascular Brasileiro
Jornal Vascular Brasileiro
Original Article

MTHFR 677C>T (rsRS1801133) variant is associated with hyperhomocysteinemia but not with clinical severity in patients with peripheral arterial disease

A variante MTHFR 677C>T (RS1801133) está associada a hiperhomocisteinemia, mas não a gravidade clínica em pacientes com doença arterial periférica

Guilherme da Silva Silvestre; Iriana Moratto Carrara; Tamires Flauzino; Marcell Alysson Batisti Lozovoy; Rubens Cecchini; Edna Maria Vissoci Reiche; Andréa Name Colado Simão

Downloads: 0
Views: 67


Background: The MTHFR 677C>T variant’s involvement with hyperhomocysteinemia and peripheral arterial disease (PAD) is still unclear.

Objectives: To evaluate associations between the MTHFR 677C>T (rs1801133) variant and susceptibility to and severity of PAD and homocysteine (Hcy) levels.

Methods: The study enrolled 157 PAD patients and 113 unrelated controls. PAD severity and anatomoradiological categories were assessed using the Fontaine classification and the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC), respectively. The variant was genotyped using real-time polymerase chain reaction and Hcy levels were determined using chemiluminescence microparticle assay.

Results: The sample of PAD patients comprised 60 (38.2%) females and 97 (61.8%) males. Patients were older and had higher Hcy than controls (median age of 69 vs. 45 years, p<0.001; and 13.66 µmol/L vs. 9.91 µmol/L, p=0.020, respectively). Hcy levels and the MTHFR 677C>T variant did not differ according to Fontaine or TASC categories. However, Hcy was higher in patients with the CT+TT genotypes than in those with the CC genotype (14.60 µmol/L vs. 12.94 µmol/L, p=0.008). Moreover, patients with the TT genotype had higher Hcy than those with the CC+CT genotypes (16.40 µmol/L vs. 13.22 µmol/L, p=0.019), independently of the major confounding variables.

Conclusions: The T allele of MTHFR 677C>T variant was associated with higher Hcy levels in PAD patients, but not in controls, suggesting a possible interaction between the MTHFR 677C>T variant and other genetic, epigenetic, or environmental factors associated with PAD, affecting modulation of Hcy metabolism.


peripheral arterial disease, methylenetetrahydrofolate reductase, homocysteine, genetic variant, Fontaine classification


Contexto: O envolvimento da variante MTHFR 677C>T na hiperhomocisteinemia e na doença arterial periférica (DAP) ainda não está claro.

Objetivos: Avaliar a associação da variante MTHFR 677C>T (rs1801133) com suscetibilidade e gravidade da DAP e valores séricos de homocisteína (Hcy).

Métodos: Este estudo caso-controle envolveu 157 pacientes com DAP e 113 controles não relacionados. A gravidade e as categorias anatomorradiológicas da DAP foram avaliadas pela classificação de Fontaine e pelo Inter-Society Consensus for the Management of Peripheral Arterial Disease, respectivamente. A genotipagem foi realizada por meio de reação em cadeia da polimerase em tempo real, e os valores de Hcy foram determinados por ensaio de micropartículas de quimioluminescência.

Resultados: Entre os pacientes com DAP, 97 (61,8%) eram homens e 60 (38,2%) eram mulheres, com mediana de idade de 69 anos. Os pacientes com DAP eram mais velhos e apresentaram valores mais elevados de Hcy do que os controles (mediana de 69 vs. 45 anos de idade, p < 0,001; 13,66 µmol/L vs. 9,91 µmol/L, p = 0,020, respectivamente). Os valores de Hcy foram mais elevados em pacientes com os genótipos CT+TT do que aqueles com o genótipo CC (14,60 µmol/L vs. 12,94 µmol/L, p = 0,008). Além disso, os pacientes com o genótipo TT apresentaram valores mais elevados de Hcy do que aqueles com os genótipos CC+CT (16,40 µmol/L vs. 13,22 µmol/L, p = 0,019, respectivamente), independentemente das principais variáveis confundidoras.

Conclusões: O alelo T da variante MTHFR 677C>T foi associado a valores mais elevados de Hcy nos pacientes com DAP, mas não em controles, sugerindo uma possível interação entre a variante genética MTHFR 677C>T e outros fatores genéticos, epigenéticos ou ambientais associados com a DAP na modulação do metabolismo da Hcy.


doença arterial periférica, metilenotetrahidrofolato redutase, homocisteína, variante genética, classificação de Fontaine


1 Breek JC, Hamming JF, De Vries J, Aquarius AE, Van Berge DP. Quality of life in patients with intermittent claudication using the world health organization questionnaire. Eur J Vasc Endovasc Surg. 2001;21(2):118-22. PMid:11237783.

2 Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109(6):733-9. PMid:14970108.

3 Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197-208. PMid:18612117.

4 Merino J, Planas A, De Moner A, et al. The association of peripheral arterial occlusive disease with major coronary events in a Mediterranean population with low coronary heart disease incidence. Eur J Vasc Endovasc Surg. 2008;36(1):71-6. PMid:18396072.

5 Fowkes FG, Murray GD, Butcher I, et al. Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. Eur J Prev Cardiol. 2014;21(3):310-20. PMid:24367001.

6 Guan X, Yang X, Wang C, Bi R. In silico analysis of the molecular regulatory networks in peripheral arterial occlusive disease. Medicine. 2020;99(21):e20404. PMid:32481342.

7 Golledge J, Biros E, Bingley J, Iyer V, Krishna SM. Epigenetics and peripheral artery disease. Curr Atheroscler Rep. 2016;18(4):1-9. PMid:26888065.

8 Krishna SM, Trollope AF, Golledge J. The relevance of epigenetics to occlusive cerebral and peripheral arterial disease. Clin Sci (Lond). 2015;128(9):537-58. PMid:25671777.

9 Wassel CL, Loomba R, Ix JH, Allison MA, Denenberg JO, Criqui MH. Family history of peripheral artery disease is associated with prevalence and severity of peripheral artery disease: the San Diego population study. J Am Coll Cardiol. 2011;58(13):1386-92. PMid:21920269.

10 Khaleghi M, Isseh IN, Bailey KR, Kullo IJ. Family history as a risk factor for peripheral arterial disease. Am J Cardiol. 2014;114(6):928-32. PMid:25107577.

11 Sofer T, Emery L, Jain D, et al. A genome-wide association study in the Hispanic Community Health Study/Study of Latinos. Sci Rep. 2019;9(1):1-11. PMid:31388106.

12 Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39(9):1764-79. PMid:8375046.

13 Spark JI, Laws P, Fritidge R. The incidence of hyperhomocysteinemia in vascular patients. Eur J Vasc Endovasc Surg. 2003;26(5):558-61. PMid:14532886.

14 Venâncio LDS, Burini RC, Yoshida WB Hiper-homocisteinemia na doença arterial periférica. J Vasc Bras. 2004;3(1):31-7.

15 Hainsworth AH, Yeo NE, Weekman EM, Wilcock DM. Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID). Biochim Biophys Acta. 2016;1862(5):1008-17. PMid:26689889.

16 Esse R, Barroso M, Tavares De Almeida I, Castro R. The Contribution of Homocysteine Metabolism Disruption to Endothelial Dysfunction: State-of-the-Art. Int J Mol Sci. 2019;20(4):867. PMid:30781581.

17 Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet. 2015;58(1):1-10. PMid:25449138.

18 Mueller T, Marschom R, Dieplinger B, et al. Leiden, Prothrombin G20210A, and MTHFR C667T mutation are not associated with chronic limb ischemia: the Linz Peripheral arterial disease (LIPAD) study. J Vasc Surg. 2005;41:808-15. PMid:15886665.

19 Khandanpour N, Willi G, Meyer FJ, Armon MP, Loke YK, Wright AJ. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: A case-control study and meta-analysis. J Vasc Surg. 2009;49(3):711-8. PMid:19157768.

20 Sabino A, Fernandes AP, Lima LM, et al. Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease. J Thromb Thrombolysis. 2009;27(1):82-7. PMid:18040753.

21 Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):1376-414. PMid:30894319.

22 Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limp-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1):S1-109, 109.e33. PMid:31182334.

23 Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(Suppl 1):S1-75. PMid:17140820.

24 Williams B, Mancia G, Spiering W, et al. ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. PMid:30165516.

25 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. PMid:11368702.

26 American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes -2021. Diabetes Care. 2021;44(Suppl 1):S15-33. PMid:33298413.

27 Frosst P, Blom HJ, Milos R, et al. A candidate gene risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111-3. PMid:7647779.

28 Riba R, Nicolaou A, Troxler M, Homer-Vaniasinkam S, Naseem KM. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis. 2004;175(1):69-75. PMid:15186948.

29 Guo XW, Dudman NPB. Homocysteine alters interactions between neutrophils and vascular endothelial cells in vitro. Atherosclerosis. 1997;134(1-2):255-255.

30 Arruda VR, Siqueira LH, Gonçalves MS, et al. Prevalence of the mutation C677 T in the methylenetetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet. 1998;78(4):332-5.<332::AID-AJMG5>3.0.CO;2-N. PMid:9714434.

31 Richter V, Janke C, Purschwitz K, et al. Plasma homocysteine and lipoprotein profile in patients with peripheral arterial occlusive disease. Angiology. 2000;51(3):189-96. PMid:10744006.

32 Cappuccio FP, Bell R, Perry IJ, et al. Homocysteine levels in men and women of different ethnic and cultural background living in England. Atherosclerosis. 2002;164(1):95-102. PMid:12119198.

33 Fowkes FG, Lee AJ, Hau CM, Cooke A, Connor JM, Lowe GD. Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh Artery Study. Atherosclerosis. 2000;150(1):179-85. PMid:10781649.

34 Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med. 2003;138(2):128-34. PMid:12529095.

35 Stricker H, Soldati G, Balmelli T, Mombelli G. Homocysteine, vitamins and gene mutations in peripheral arterial disease. Blood Coagul Fibrinolysis. 2001;12(6):469-75. PMid:11555700.

36 Leeper NJ, Kullo IJ, Cooke JP. Genetics of peripheral artery disease. Circulation. 2012;125(25):3220-8. PMid:22733336.

37 Belkin N, Damrauer SM. Peripheral arterial disease genetics: progress to date and challenges ahead. Curr Cardiol Rep. 2017;19(12):131. PMid:29094207.

38 Castro R, Rivera I, Ravasco P, et al. 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C → T and 1298A → C mutations are associated with DNA hypomethylation. J Med Genetics. 2004;41(6):454-8. PMID: 15173232.

39 Sam RC, Burns PJ, Hobbs SD, et al. The prevalence of hyperhomocysteinemia. methylene tetrahydrofolate reductase C677T mutation. and vitamin B12 and folate deficiency in patients with chronic venous insufficiency. J Vasc Surg. 2003;38(5):904-8. PMid:14603192.

40 Wilmanns C, Casey A, Schinzel H, Walter PK. Superficial thrombophlebitis in varicose vein disease: the particular role of methylenetetrahydrofolate reductase. Phlebology. 2011;26(4):135-9. PMid:20881312.

Submitted date:

Accepted date:

Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)"> Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)">
65567979a953954eac608e23 jvb Articles
Links & Downloads

J Vasc Bras

Share this page
Page Sections